Synopsis: Blue Jet HealthCare reported a steep sequential decline in revenue and profit in Q2FY26 due to de-stocking in the PI segment, though gross margins and other income improved sharply. Despite steady progress on capacity expansion and product launches, investors reacted to near term weakness, with the stock hitting its 10 percent lower circuit.

A pharma CDMO (Contract Development and Manufacturing Organization) stock fell sharply after Q2 results, as investors reacted to a significant quarter-on-quarter drop in sales and operating profit despite higher gross margins and a surge in other income. The muted topline reflected temporary de-stocking in the PI segment.

Blue Jet HealthCare Ltd reported a market capitalisation of Rs. 10,534.56 crore. The stock opened at Rs. 679.95 and hi

See Full Page